U.S. Food and Drug Administration Approves Haegarda (C1 Esterase Inhibitor Subcutaneous [Human]) for Prevention of Hereditary Angioedema (HAE) Attacks in Pediatric Patients

KING OF PRUSSIA, PA  – September 28, 2020 – CSL Behring, a global biotherapeutics leader, announced today that the U.S.

Read more